

Cite this as: Xiaobai HE, Xinyi QIAN, Xiaoguang ZHENG, Hong ZHANG, Jinbang SHAO, Xiaopan CHEN, Qi RUAN, Jianxin LYU, Leixiang YANG, Linjie CHEN. Selenocystine-based fluorescence assay combined with structural prediction for functional analysis of cystine transporter variants in cystinuria. *Journal of Zhejiang University-SCIENCE B*, 2026, 27(7):806-816. <https://doi.org/10.1631/jzus.B2500767>

Selenocystine-based fluorescence assay combined with structural prediction for functional analysis of cystine transporter variants in cystinuria

Key words: Cystinuria; *SLC3A1*; *SLC7A9*; Selenocystine; Diagnosis; Mutation

■ PAPER SUMMARY

A nonradioactive route to cystinuria variant function


Selenocystine fluorescence assay + AlphaFold3 structural interpretation for SLC3A1/SLC7A9 variants

Clinical gap

Radioisotope assays and mass spectrometry are difficult to scale for routine variant interpretation.

Platform answer

A microplate-readable fluorescent surrogate measures transporter activity and connects the signal to structural mechanisms.



Mechanism of $b^{0,+}AT$ -rBAT Transporter Dysfunction in Cystinuria

1%-2%

adult kidney stones
cystine stones

up to 10%

pediatric stones
reported burden

460+


reported pathogenic mutations

HGMD: SLC3A1 + SLC7A9

■ ASSAY DESIGN

Selenocystine converts transporter uptake into a microplate signal

The workflow replaces radioactive cystine uptake with a cell-based fluorescent readout compatible with standard laboratory infrastructure.



nonradioactive

30 min uptake

535 nm readout

variant-ready

Innovation

Selenocystine acts as a cystine analog, but its selenium chemistry creates a sensitive fluorescence handle after cellular uptake.

■ VALIDATION

Selenocystine behaves like cystine, but is much easier to see

Selenocystine produced a high-sensitivity signal while retaining transporter competition and selectivity patterns expected for SLC3A1/SLC7A9.

>100-fold

stronger in-vitro fluorescence

Se-CssC vs cystine

Km 156.3 +/- 24.2

umol/L apparent affinity

near literature cystine Km ~200

7.65 +/- 0.45x

Vmax over base value

saturable uptake

25 umol/L

detectable uptake

cystine not detectable at 600


Remaining signal after competition tracks substrate identity

cystine



~50% signal at 1:1 mix

ornithine / lysine / arginine



low residual signal

neutral / acidic amino acids



signal mostly retained

Interpretation: the fluorescent surrogate is not just visible; it follows the expected amino-acid transport logic.

■ VARIANT STRATIFICATION

Clinical variants separate into functional severity bands

Operational thresholds translated residual transport into mild, moderate, or severe functional categories consistent with prior radioisotope-based reports.

MILD

>60% residual activity

SLC7A9 A70V

SLC7A9 A182T

MODERATE

20%-60% residual activity

SLC7A9 G105R

SLC7A9 R333W

SEVERE


<20% residual activity

SLC7A9 P482L

SLC7A9 V170M

SLC7A9 A354T

SLC3A1 M467T



Why it matters

A scalable activity readout can help reclassify cystinuria variants and prioritize follow-up for genotype-guided care.

Function plus structure turns VUS triage into a testable pathway


The assay supplies measured activity; AlphaFold3/docking adds mechanistic hypotheses when predictions are discrete and locally confident.

P482L: channel occlusion

Bulky leucine protrudes into the predicted substrate path.

~5% wild-type activity retained

While **P482G** remains open and retains ~100%, acting as an internal contrast.



Workflow

